ALT and CDX: Why these ASX healthcare stocks were in news today

Highlights Beamtree has signed a five-year deal with Ampath for the implementation of its RippleDown software.  The total value of the contract is AU$9.7 million.  Backed by the announcement, the share price of Beamtree has gained mo...

Highlights Dividend stocks are a regular flow of income source from investments A dividend is a pay-out of a certain portion of a Company's profit to its investors Stocks paying good dividends give you a stable portfolio Investing in divi...

Highlights Growth stocks are shares of the company estimated to increase sales and earnings faster than the market These stocks are likely to provide good price appreciation in the future Growth stocks also serve as a good hedge against inflat...

Highlights 3D printing technology is used in developing new surgical cuttings, patient-specific replicas of bones, organs and blood vessels The innovative technology has created long-lasting and better-fitting implants 3D printers that can rep...

In a significant development, Clinuvel Pharmaceuticals Ltd (ASX: CUV) received positive results from the clinical study evaluating its drug afamelanotide in arterial ischemic stroke (AIS). The open label final study (CUV 801), the first clinical s...

Medical technologies assist healthcare professionals in diagnosing and treating patients with a higher level of accuracy and on time. The next generation of medical technologies holds great potential in advancing the entire health care industry. T...

Highlights AGN continued preclinical work targeting the potential use of ARG-007 in other kinds of brain injuries PYC initiated GLP toxicology studies in the RP11 program to support IND submission in 2H 2022 Kazia launched an ATM facility in c...

>   The shares of cannabis-focused drug development and product innovation company Bod Australia Limited (ASX:BOD) are gaining attention following its Q3 FY2022 update. BOD shares traded flat at AU$0.170 per share at 3:36 PM AEST today. ...

Highlights: ResMed released its unaudited Q3 FY22 results today, stating a 14% gain in revenue.  ResMed’s earnings per share stand at AU$1.22 per share in the given period.  The company will further pay a quarterly dividend wor...

Highlights: Starpharma is working closely with LloydsPharmacy to bring VIRALEZE back in the UK by this quarter. Starpharma has recorded AU$3.6 million rise in the cash balance within a quarter. The company has reported receipts of AU$9.6 milli...